Vasoactive peptides (Katzung) Flashcards
Renin Release Blockers
Clonidine
Propranolol
Renin Release Blockers - Effects
Arteriolar dilation
Decreased aldosterone secretion
Increased sodium and water excretion
Renin Release Blockers - Clinical use
Hypertension
Clonidine - MoA
Causing a centrally mediated reduction in renal sympathetic nerve activity, and it may also exert a direct intrarenal action.
Propranolol - MoA
Blocking the intrarenal and extrarenal β receptors involved in the neural control of renin release.
Angiotensin Receptor Antagonists
Losartan Valsartan Eprosartan Irbesartan Candasartan Olmesatran Telmisartan
Angiotensin Receptor Antagonists - MoA
Selective competitive antagonist of angiotensin AT1 receptors
Angiotensin Receptor Antagonists - Effects
Arteriolar dilation
Decreased aldosterone secretion
Increased sodium and water excretion
Angiotensin Receptor Antagonists - Clinical use
Hypertension
Diabetic nephropathy
Heart failure (Alternative when ACE inhibitors are not tolerated)
Combination therapy with an ACE inhibitor
Angiotensin Receptor Antagonists - Adverse effects and Contraindication
Cough (low incidence)
Sprue-like enteropathy
Contraindication: Nondiabetic renal disease and pregnancy
Losartan - Clinical use
Marfan syndrome (By blocking ANG II, which decrease TGF-β, which is usually increased in Marfan syndrome)
Valsartan - Clinical use
Decrease the incidence of diabetes in patients with impaired glucose tolerance.
Angiotensin-Converting Enzyme Inhibitors
Enalapril
Captopril
Angiotensin-Converting Enzyme Inhibitors - MoA
Inhibits conversion of angiotensin I to angiotensin II
They also inhibit the degradation of other substances, including bradykinin, substance P, and enkephalins.
Angiotensin-Converting Enzyme Inhibitors - Effects
Arteriolar dilation
Decreased aldosterone secretion
Increased sodium and water excretion
Angiotensin-Converting Enzyme Inhibitors - Clinical use
Hypertension
Heart failure
Left Ventricular dysfunction
Diabetic nephropathy
Angiotensin-Converting Enzyme Inhibitors - Adverse effects and Contraindications
Cough
Angioedema
Contraindications: Pregnancy because they cause fetal kidney damage.
Renin Inhibitors
Aliskiren
Renin Inhibitors - MoA
Inhibits plasma renin activity
Renin Inhibitors - Effects
Arteriolar dilation
Decreased aldosterone secretion
Increased sodium and water excretion
Renin Inhibitors - Clinical use
Hypertension
Aliskiren - Contraindication
Pregnancy
Kinin Inhibitors
Icatibant
Ecallantide
Cinryze, Berinert
Aprotinin
Kinin Inhibitors - MoA
Selective antagonist of kinin B2 receptors
Kinin Inhibitors - Effects
Blocks effects of kinins on pain, hyperalgesia, and inflammation
Kinin Inhibitors - Clinical use
Hereditary angioedema
Icatibant - Clinical use
Drug-induced angioedema Airway disease Thermal injury Ascites Pancreatitis
Which kinin inhibitor is a plasma kallikrein inhibitor
Ecallantide
Which kinin inhibitor is a kinin synthesis inhibitor
Aprotinin
Vasopressin Agonists
Arginine vasopressin
Terlipressin
Selepressin
Vasopressin Agonists - MoA
Agonist of vasopressin V1 (and V2) receptors
Vasopressin Agonists - Effects
Vasoconstriction
Vasopressin Agonists - Clinical use
Vasodilatory shock
Arginine vasopressin - MoA
Selective V2 antidiuretic analog
Terlipressin - MoA
More selective for V1 receptor but also stimulate V2 receptors
Selepressin - MoA
Selective V1a receptor agonist
Selepressin - Clinical use
Septic shock
Vasopressin Antagonists
Conivaptan
Relcovaptan
Tolvaptan
Vasopressin Antagonists - MoA
Antagonist of vasopressin V1 (and V2) receptors
Vasopressin Antagonists - Effects
Vasodilation
Vasopressin Antagonists - Clinical use
Potential use in Raynaud`s disease, hypertension, heart failure, brain edema and hyponatremia
Conivaptan - MoA
Selective V1 receptor antagonist
Relcovaptan - MoA
V1 and V2 receptor antagonist
Tolvaptan - MoA
V2 receptor antagonist
Natriuretic Peptides
Carperitide
Nesiritide
Uraritide
Natriuretic Peptides - MoA
Agonist of natriuretic peptide receptors
Natriuretic Peptides - Effects
Increased sodium and water excretion
Vasodilation
Natriuretic Peptides - Clinical use
Heart failure
Carperitide - MoA
Recombinant ANP
Nesiritide - MoA
Recombinant BNP
Vasopeptidase Inhibitors
Omapatrilat
Sampatrilat
Fasidotrilat
Vasopeptidase Inhibitors - MoA
Inhibit Neprilysin and ACE
Vasopeptidase Inhibitors - Effects
Vasodilation
Increased sodium and water excretion
Vasopeptidase Inhibitors - Clinical use
Hypertension
Heart failure
Endothelin Antagonists
Bosentan
Sitaxsentan
Ambrisentan
Phosphoramidon
Endothelin Antagonists - MoA
Nonselective antagonist of endothelin ETA and ETB receptors
Endothelin Antagonists - Effects
Vasodilation and decreased arterial pressure
Endothelin Antagonists - Clinical use
Pulmonary arterial hypertension
Other conditions (Although not very effective): Resistant hypertension Chronic renal disease Connective tissue disease Subarachnoid hemorrhage
Endothelin Antagonists - Adverse effects
Dose-dependent hepatotoxicity Systemic hypotension Increased heart rate Facial flushing or edema Headaches GI effects
Endothelin Antagonists - Contraindications
Pregnancy because of teratogenic effects
Bosentan - MoA
Nonselective antagonist of endothelin ETA and ETB receptors
Bosentan - Adverse effects
Fatal hepatotoxicity (Patients should have monthly liver functions test)
Sitaxsentan, Ambrisentan - MoA
Selective for ETA receptors
Phosphoramidon - MoA
Block formation of endothelins by inhibiting endothelin-converting enzyme
Vasoactive Intestinal Peptide Agonists
PB1046 (Vasomera)
Vasoactive Intestinal Peptide Agonists - MoA
Agonist of VPAC1 and VPAC2 receptors
Vasoactive Intestinal Peptide Agonists - Effects
Smooth muscle relaxation and vasodilation
Multiple metabolic, endocrine, and other effects
Vasoactive Intestinal Peptide Agonists - Clinical use
Systemic and pulmonary hypertension and Heart failure
Vasoactive Intestinal Peptide Agonists - Adverse effects
Hypotension
PB1046 (Vasomera) - MoA
Long-acting selective VPAC2 receptor agonist
PB1046 (Vasomera) - Effects
Reduces blood pressure
Substance P Antagonists
Aprepitant
Fosaprepitant
Substance P Antagonists - MoA
Selective antagonist of tachykinin NK1 receptors
Substance P Antagonists - Effects
Blocks several central nervous system effects of substance P
Substance P Antagonists - Clinical use
Prevention of chemotherapy- induced and postoperative nausea and vomiting, as well as Depression and Cancer
Neurotensin Agonists
PD149163
Neurotensin Agonists - MoA
Agonist of central neurotensin receptors
Neurotensin Agonists - Effects
Interacts with central dopamine systems
Neurotensin Agonists - Clinical use
Potential for treatment of schizophrenia and Parkinson’s disease
Neurotensin Agonists - Adverse effects
Hypothermia and Hypotension
Neurotensin Antagonists
Meclinertant
Neurotensin Antagonists - MoA
Antagonist of central and peripheral neurotensin receptors
Neurotensin Antagonists - Effects
Blocks some central and peripheral (vasodilator) actions of neurotensin
Neurotensin Antagonists - Clinical use
None identified
Calcitonin Gene-Related Peptide Antagonists
Telcagepant
Olcegepant
Calcitonin Gene-Related Peptide Antagonists - MoA
Antagonists of the calcitonin gene-related peptide (CGRP) receptor
Calcitonin Gene-Related Peptide Antagonists - Effects
Blocks some central and peripheral (vasodilator) actions of CGRP
Calcitonin Gene-Related Peptide Antagonists - Clinical use
Migraine
Telcagepant - Adverse effects
Liver toxicity
Neuropeptide Y Antagonists
BIBP3226
BIIE0246
MK-0557
Neuropeptide Y Antagonists - MoA
Selective antagonist of neuropeptide Y1 receptors
Neuropeptide Y Antagonists - Effects
Blocks vasoconstrictor response to NPY
Neuropeptide Y Antagonists - Clinical use
Potential Antiobesity agent
BIIE0246 - MoA
Selective for Y2 receptor
MK-0557 - MoA
Selective for Y5 receptor
Urotensin Antagonist
Urantide
Palosuran
Urotensin Antagonist - MoA
Antagonist of urotensin receptors
Urotensin Antagonist - Effects
Blocks vasoconstrictor action of urotensin
Urotensin Antagonist - Clinical use
Beneficial in renal failure
-Not in hypertensive patients with type 2 diabetic nephropathy
Palosuran - Clinical use
Diabetic renal failure